이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

JiangSu WuZhong Pharmaceutical Development 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Qunshan Qian

최고 경영자

CN¥1.3m

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

Recent updates

JiangSu WuZhong Pharmaceutical Development (SHSE:600200) Is Making Moderate Use Of Debt

Jun 06

Many Still Looking Away From JiangSu WuZhong Pharmaceutical Development Co., Ltd. (SHSE:600200)

Mar 12

CEO

Qunshan Qian (51 yo)

no data

테뉴어

CN¥1,284,000

보상

Mr. Qunshan Qian is Chairman & CEO of JiangSu WuZhong Pharmaceutical Development Co., Ltd.

JiangSu WuZhong Pharmaceutical Development 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

JiangSu WuZhong Pharmaceutical Development Co., Ltd., Annual General Meeting, May 16, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

JiangSu WuZhong Pharmaceutical Development Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

JiangSu WuZhong Pharmaceutical Development (SHSE:600200) Is Making Moderate Use Of Debt

JiangSu WuZhong Pharmaceutical Development Co., Ltd., Annual General Meeting, May 16, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

JiangSu WuZhong Pharmaceutical Development Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Many Still Looking Away From JiangSu WuZhong Pharmaceutical Development Co., Ltd. (SHSE:600200)

New major risk - Share price stability

JiangSu WuZhong Pharmaceutical Development Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: CN¥0.022 loss per share (vs CN¥0.04 loss in 3Q 2022)

JiangSu WuZhong Pharmaceutical Development Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Second quarter 2023 earnings released: CN¥0.001 loss per share (vs CN¥0.036 loss in 2Q 2022)

JiangSu WuZhong Pharmaceutical Development Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Cinkate Medicine Chemical Intermediate (Shanghai) Co., Ltd. agreed to acquire 15% stake in Suzhou Changzheng Cinkate Pharmaceutical Co., Ltd. from JiangSu WuZhong Pharmaceutical Development Co., Ltd. (SHSE:600200) for CNY 33 million.

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.04 loss per share (vs CN¥0.028 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.036 loss per share (vs CN¥0.036 loss in 2Q 2021)

Less than half of directors are independent

Third quarter 2021 earnings released: CN¥0.028 loss per share (vs CN¥0.039 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.036 loss per share (vs CN¥0.035 loss in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.011 in 1Q 2020)

New 90-day low: CN¥4.71

New 90-day low: CN¥5.10

Third quarter 2020 earnings released: CN¥0.04 loss per share

Jiangsu Wuzhong Industrial Co., Ltd to Report Q3, 2020 Results on Oct 31, 2020

New 90-day low: CN¥5.88

New 90-day low: CN¥5.99

New 90-day low - CN¥6.23

Jiangsu Wuzhong Industrial Co., Ltd to Report First Half, 2020 Results on Aug 28, 2020

CEO

테뉴어

보상